Kernel is developing non-invasive neuroimaging technology for research and enterprise applications, founded by Braintree co-founder Bryan Johnson. The company's Kernel Flow system uses time-domain fNIRS to measure hemodynamic brain activity at high temporal resolution across a full-head array. Johnson self-funded the company with $53M in 2020. Kernel targets pharmaceutical companies needing objective neural biomarkers for clinical trials, neuroscience research institutions, and enterprise brain health monitoring. Bryan Johnson is also known for Project Blueprint, his longevity optimization program.